Literature DB >> 28381915

Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women.

Clayton English, Anne Muhleisen, Jose A Rey.   

Abstract

Flibanserin (Addyi) for female sexual interest/arousal disorder in premenopausal women.

Entities:  

Year:  2017        PMID： 28381915      PMCID： PMC5358680     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  16 in total

Review 1.  Circuits of sexual desire in hypoactive sexual desire disorder.

Authors:  Stephen M Stahl
Journal:  J Clin Psychiatry       Date:  2010-05       Impact factor: 4.384

Review 2.  Diagnosis and treatment of female sexual dysfunction.

Authors:  Jennifer E Frank; Patricia Mistretta; Joshua Will
Journal:  Am Fam Physician       Date:  2008-03-01       Impact factor: 3.292

3.  Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study.

Authors:  Leonard R Derogatis; Lawrence Komer; Molly Katz; Michèle Moreau; Toshio Kimura; Miguel Garcia; Glen Wunderlich; Robert Pyke
Journal:  J Sex Med       Date:  2012-01-16       Impact factor: 3.802

4.  Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study.

Authors:  John Thorp; James Simon; Dan Dattani; Leslie Taylor; Toshio Kimura; Miguel Garcia; Lynna Lesko; Robert Pyke
Journal:  J Sex Med       Date:  2012-01-12       Impact factor: 3.802

5.  Lack of interaction between flibanserin and antidepressants in inducing serotonergic syndrome in rats.

Authors:  F Borsini; A Brambilla; R Cesana; N Grippa
Journal:  Int J Neuropsychopharmacol       Date:  2001-03       Impact factor: 5.176

6.  Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial.

Authors:  James A Simon; Sheryl A Kingsberg; Brad Shumel; Vladimir Hanes; Miguel Garcia; Michael Sand
Journal:  Menopause       Date:  2014-06       Impact factor: 2.953

7.  Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial.

Authors:  Molly Katz; Leonard R DeRogatis; Ronald Ackerman; Parke Hedges; Lynna Lesko; Miguel Garcia; Michael Sand
Journal:  J Sex Med       Date:  2013-05-14       Impact factor: 3.802

8.  Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women.

Authors:  Suzanne L West; Aimee A D'Aloisio; Robert P Agans; William D Kalsbeek; Natalie N Borisov; John M Thorp
Journal:  Arch Intern Med       Date:  2008-07-14

Review 9.  Hypoactive sexual desire disorder in women: treatment options beyond testosterone and approaches to communicating with patients on sexual health.

Authors:  Nicole M Lodise
Journal:  Pharmacotherapy       Date:  2013-04       Impact factor: 4.705

10.  Sexual functioning and practices in a multi-ethnic study of midlife women: baseline results from SWAN.

Authors:  Virginia S Cain; Catherine B Johannes; Nancy E Avis; Beth Mohr; Miriam Schocken; Joan Skurnick; Marcia Ory
Journal:  J Sex Res       Date:  2003-08
View more
  3 in total

1.  Optimized Nanostructured Lipid Carriers Integrated into In Situ Nasal Gel for Enhancing Brain Delivery of Flibanserin.

Authors:  Usama A Fahmy; Osama A A Ahmed; Shaimaa M Badr-Eldin; Hibah M Aldawsari; Solomon Z Okbazghi; Zuhier A Awan; Muhammed A Bakhrebah; Mohammad N Alomary; Wesam H Abdulaal; Carlos Medina; Nabil A Alhakamy
Journal:  Int J Nanomedicine       Date:  2020-07-24

Review 2.  Bremelanotide for Treatment of Female Hypoactive Sexual Desire.

Authors:  Amber N Edinoff; Nicole M Sanders; Kyle B Lewis; Tucker L Apgar; Elyse M Cornett; Adam M Kaye; Alan D Kaye
Journal:  Neurol Int       Date:  2022-01-04

3.  Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and in vivo pharmacokinetic study.

Authors:  Marianne J Naguib; Amal I A Makhlouf
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.